Akebia Therapeutics Inc. Common Stock (AKBA)
Stock · NASDAQ · Health Care
$0.6704as of 10/16/2026
Price chart
Active signals
AKBA Signal Track Record
How signals performed across all stocks →What AKBA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +0.9% | 52% | August 27, 2026 |
| Bollinger Band Breakout | 27 | 0.0% | 48% | September 2, 2026 |
| Bollinger Band BreakdownActive now | 15 | -1.4% | 40% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -1.5% | 44% | October 1, 2025 |
| Any 20-session window (baseline) | -0.7% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric cit…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 194
- Website
- akebia.com/
Fundamentals
- 1-day range
- $0.6659$0.7326
- Market cap
- $256.03M
- P/E (trailing)
- —
- P/E (forward)
- -1.86
- EPS (trailing)
- $-0.11
- Dividend yield
- —
- Beta
- 0.20
- Avg. volume
- 6.63M
How Akebia Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Akebia Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
- RNACCartesian Therapeutics Inc. Common Stock$6.27▼ 4.71%Market cap $257.38MP/E —$5.6$11
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
| RNAC Cartesian Therapeutics Inc. Common Stock | $257.38M | — | $6.27 | ▼ 4.71% | $5.6$11 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumYahoo · 10/7/2026
- Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026Yahoo · 10/6/2026
- SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of DirectorsYahoo · 9/22/2026
- SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & DevelopmentYahoo · 9/15/2026
- BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price TargetBenzinga · 9/15/2026
- Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesYahoo · 9/14/2026
- Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney DiseasesBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Butler John P. · August 6, 2026 · Option Exercise350.0K @ $0.63
- Ostrowski Erik · June 29, 2026 · Sale56.0K @ $1.11
- FRIESON RON · June 17, 2026 · Grant53.6K
- FRIESON RON · June 17, 2026 · Grant35.7K
- Wolf Myles · June 17, 2026 · Grant53.6K
- Wolf Myles · June 17, 2026 · Grant35.7K
- Smith Cynthia · June 17, 2026 · Grant53.6K
- Smith Cynthia · June 17, 2026 · Grant35.7K
- Adrian Adams · June 17, 2026 · Grant53.6K
- Adrian Adams · June 17, 2026 · Grant35.7K
- ROGERS MICHAEL W · June 17, 2026 · Grant53.6K
- ROGERS MICHAEL W · June 17, 2026 · Grant35.7K
- ZUMWALT LEANNE M · June 17, 2026 · Grant53.6K
- ZUMWALT LEANNE M · June 17, 2026 · Grant35.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 98.35M
- Total value held
- $132.78M
- Institutional holders
- 167
- Unknown18.69M
- Unknown11.61M
- Unknown11.17M
- Unknown6.45M
- Unknown3.60M
- Unknown2.85M
- Unknown2.76M
- Unknown2.40M
- Unknown2.38M
- Unknown2.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week
In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.